®
Ovid Therapeutics
Corporate Overview
(NASDAQ: OVID)
©2023 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED | JANUARY 2023 |
Disclaimers and forward-looking statements
This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the timing and development of Ovid's product candidate pipeline and achievement of expected near- and long-term milestones; the potential therapeutic benefits of
Ovid's current or future product candidates and pipeline programs; the reporting of preclinical data for OV329; the reporting of data for Phase 1 study in healthy volunteers for OV329; the potential use of OV329 to treat rare and treatment-resistant forms of epilepsy and seizures; the clinical and regulatory development of OV329, including the anticipated timing of clinical trials of OV329 and other KCC2 compounds in the Company's library; the likelihood that data for OV329 will support future development and therapeutic potential; the potential development of OV350; the suitability of the Company's library of novel, direct KCC2 transporter activators for a range of formulations and administrations that would make it possible to pursue both chronic and acute epilepsies; the timing for filing of the Company's IND applications; the potential benefits of
Gensaic's proprietary phage-derived platform; the timing for the completion of Takeda's two pivotal Phase 3 trials evaluating soticlestat for Lennox-Gastaut and Dravet syndromes; the success of Takeda's trials in soticlestat; the duration of the Company's cash runway, and the expectation that it will support the advancement of the Company's pipeline; Ovid's business development intentions; the success of any licensing or partnering opportunities, the success, timing, ability to attract and maintain strategic collaborations; the clinical and regulatory development and potential commercialization of soticlestat, OV350, or any of Ovid's other current or future product candidates and pipeline programs and market opportunities You can identify forward-looking statements because they contain words such as "will," "plan", "believes", intends," "anticipates," "strives," "pursue," "design," "advance," "target," "seek," "expects," and "potential" and similar expressions (as well as other words or expressions referencing future events,
conditions or circumstances).
Forward-looking statements are based on Ovid's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid's ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its technology or its business strategy, risks related to Ovid's ability to identify business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any business development transactions and risks to Ovid's or any of its partners' abilities to meet anticipated deadlines and milestones presented by the ongoing COVID-19 pandemic. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption "Risk Factors" in Ovid's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 8, 2022, and in future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
The trademarks included in this presentation are the property of the owners thereof and are used for reference purposes only.
©2023 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED | 2 | |
Focused epilepsy pipeline | |||||||
with significant unmet need & large | |||||||
addressable market | |||||||
Substantial milestones & royalties | |||||||
due from Takeda surrounding potential | |||||||
® | |||||||
regulatory approval & commercial sales | |||||||
of soticlestat | |||||||
Transforming the lives of | Veteran team | ||||||
individuals with epilepsies | |||||||
& rare neurological | with track record of value creation | ||||||
diseases | & transformative transactions | ||||||
Cash runway into 2025 | |||||||
& disciplined approach to | |||||||
business development | |||||||
3 | |||||||
©2023 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED | |||||||
Epilepsy market is a promising opportunity
Significant patient need
30 - 40%
of individuals have seizures not controlled with anti- seizure medicines1
De-risked development
Validated & emerging targets cause neuronal hyperexcitability
Small molecules that can cross the blood-brain barrier
Large addressable market
65 million
people living with epilepsy worldwide3
47%
of patients take 5 medicines on average, demonstrating need for unique, well tolerated anti- seizure mechanisms2
Predictive, clinically- translatable seizure models
Hard endpoints (seizures) and biomarkers
3 million
people living with epilepsy in US4
- Huron Primary Research (11/2019-12/2019)
- Terman SW, Aubert CE, Hill CE, et al. Polypharmacy in patients with epilepsy: a nationally representative cross-sectional study. Epilepsy Behav. 2020;111:107261.
- Epilepsy fast facts. Centers for Disease Contr Easl and Prevention. Updated September 30, 2020. Accessed July 12, 2022.https://www.cdc.gov/epilepsy/about/fast-facts.htm.
- CDC Epilepsy data:https://www.cdc.gov/epilepsy/data/index.html
- Global Data Report, Epilepsy: Global Drug Forecast and Market Analysis to 2030 - Forecast Update
©2023 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED
>$8B
global market opportunity5
4
Advancing epilepsy pipeline | Small molecule | ||||||
Genetic target | |||||||
SMALL MOLECULE | INDICATION/TARGET | PRECLINICAL | PHASE 1 | PHASE 2 | PHASE 3 | ANTICIPATED | |
MILESTONES | |||||||
OUT-LICENSED TO | Dravet syndrome | • | Phase 3 data from 2 | ||||
SOTICLESTAT | registrational trials | ||||||
Filing marketing | |||||||
CH24H inhibitor | • | ||||||
Lennox-Gastaut syndrome | authorization submissions | ||||||
in Takeda's FY 2024 | |||||||
OV329 | Tuberous Sclerosis Complex, infantile | • | Phase 1 target | ||||
GABA-aminotransferase | engagement & safety | ||||||
spasms and focal seizures | |||||||
inhibitor | findings - H1 2024 | ||||||
IN-LICENSED FROM | |||||||
OV350 | Resistant epilepsies and other | • | Anticipated IND in 2024 | ||||
neuro-pathologies | |||||||
KCC2 transporter activator | |||||||
NUCLEIC ACID | INDICATION / TARGET | PRECLINICAL | PHASE 1 | PHASE 2 | PHASE 3 | MILESTONE | |
OV882 | Angelman syndrome | ||||||
Collaborator: UCONN | |||||||
OV815 | KAND - KIF1A associated-neurological | ||||||
Collaborator: Columbia Univ. | disorders |
OV825 HNRNPH2
Collaborator: Columbia Univ.
UNDISCLOSED PROGRAMS WITH COLUMBIA UNIVERSITY & RESEARCH
COLLABORATION WITH GENSAIC
STRATEGIC BUSINESS DEVELOPMENT ACTIVITIES FOCUSED ON COMPLEMENTING OUR GENETIC TARGETS & AUGMENTING CLINICAL STAGE ASSETS
©2023 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED | 5 | |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Ovid Therapeutics Inc. published this content on 09 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 January 2023 12:08:15 UTC.